Skip to content

Resources

Jump to bottom
Lucie Contamin edited this page Oct 3, 2024 · 5 revisions

RSV resources

RSV Data

RSV publication

  • Curns, Aaron T., Brian Rha, Joana Y. Lively, Leila C. Sahni, Janet A. Englund, Geoffrey A. Weinberg, Natasha B. Halasa, et al. 2024. “Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020.” Pediatrics 153 (3): e2023062574. https://doi.org/10.1542/peds.2023-062574

  • “Full Article: A Population-Weighted, Condition-Adjusted Estimate of Palivizumab Efficacy in Preventing RSV-Related Hospitalizations among US High-Risk Children.” n.d. Accessed October 27, 2023. https://www.tandfonline.com/doi/full/10.4161/hv.32082

  • Glezen, W. P., L. H. Taber, A. L. Frank, and J. A. Kasel. 1986. “Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus.” American Journal of Diseases of Children (1960) 140 (6): 543–46. https://doi.org/10.1001/archpedi.1986.02140200053026

  • Griffin, M. Pamela, Yuan Yuan, Therese Takas, Joseph B. Domachowske, Shabir A. Madhi, Paolo Manzoni, Eric A.F. Simões, et al. 2020. “Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.” New England Journal of Medicine 383 (5): 415–25. https://doi.org/10.1056/NEJMoa1913556

  • Hall, C. B., E. E. Walsh, C. E. Long, and K. C. Schnabel. 1991. “Immunity to and Frequency of Reinfection with Respiratory Syncytial Virus.” The Journal of Infectious Diseases 163 (4): 693–98. https://doi.org/10.1093/infdis/163.4.693

  • Hall, Caroline Breese, Geoffrey A. Weinberg, Marika K. Iwane, Aaron K. Blumkin, Kathryn M. Edwards, Mary A. Staat, Peggy Auinger, et al. 2009. “The Burden of Respiratory Syncytial Virus Infection in Young Children.” The New England Journal of Medicine 360 (6): 588–98. https://doi.org/10.1056/NEJMoa0804877

  • Hammitt, Laura L., Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva, Shabir A. Madhi, William J. Muller, et al. 2022. “Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.” New England Journal of Medicine 386 (9): 837–46. https://doi.org/10.1056/NEJMoa2110275

  • “Health Alert Network (HAN) - 00499 | Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season.” 2023. October 23, 2023. https://emergency.cdc.gov/han/2023/han00499.asp#:~:text=In%20the%20context%20of%20limited,risk%20for%20severe%20RSV%20disease

  • Hodgson, David, Neil Wilkins, Edwin van Leeuwen, Conall H. Watson, Jonathan Crofts, Stefan Flasche, Mark Jit, and Katherine E. Atkins. 2024. “Protecting Infants against RSV Disease: An Impact and Cost-Effectiveness Comparison of Long-Acting Monoclonal Antibodies and Maternal Vaccination.” The Lancet Regional Health. Europe 38 (March):100829. https://doi.org/10.1016/j.lanepe.2023.100829

  • Ison, Michael G., Alberto Papi, Eugene Athan, Robert G. Feldman, Joanne M. Langley, Dong-Gun Lee, Isabel Leroux-Roels, et al. 2024. “Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 78 (6): 1732–44. https://doi.org/10.1093/cid/ciae010

  • Jackson, Michael L, Emily Scott, Jane Kuypers, Arun K Nalla, Pavitra Roychoudury, and Helen Y Chu. 2021. “Epidemiology of Respiratory Syncytial Virus Across Five Influenza Seasons Among Adults and Children One Year of Age and Older—Washington State, 2011/2012–2015/2016.” The Journal of Infectious Diseases 223 (1): 147–56. https://doi.org/10.1093/infdis/jiaa331

  • Jones, Jefferson M. 2023. “Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023.” MMWR. Morbidity and Mortality Weekly Report 72. https://doi.org/10.15585/mmwr.mm7234a4

  • Kampmann, Beate, Shabir A. Madhi, Iona Munjal, Eric A. F. Simões, Barbara A. Pahud, Conrado Llapur, Jeffrey Baker, et al. 2023. “Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.” New England Journal of Medicine 388 (16): 1451–64. https://doi.org/10.1056/NEJMoa2216480

  • Lang, John C. 2022. “Use of Mathematical Modelling to Assess Respiratory Syncytial Virus Epidemiology and Interventions: A Literature Review.” Journal of Mathematical Biology 84 (4): 26. https://doi.org/10.1007/s00285-021-01706-y

  • McLaughlin, John M, Farid Khan, Elizabeth Begier, David L Swerdlow, Luis Jodar, and Ann R Falsey. 2022. “Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-Analysis.” Open Forum Infectious Diseases 9 (7): ofac300. https://doi.org/10.1093/ofid/ofac300

  • Melgar, Michael. 2023. “Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023.” MMWR. Morbidity and Mortality Weekly Report 72. https://doi.org/10.15585/mmwr.mm7229a4

  • Nokes, D. James, Emelda A. Okiro, Mwanajuma Ngama, Lisa J. White, Rachel Ochola, Paul D. Scott, Patricia A. Cane, and Graham F. Medley. 2004. “Respiratory Syncytial Virus Epidemiology in a Birth Cohort from Kilifi District, Kenya: Infection during the First Year of Life.” The Journal of Infectious Diseases 190 (10): 1828–32. https://doi.org/10.1086/425040

  • Papi, Alberto, Michael G. Ison, Joanne M. Langley, Dong-Gun Lee, Isabel Leroux-Roels, Federico Martinon-Torres, Tino F. Schwarz, et al. 2023. “Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.” New England Journal of Medicine 388 (7): 595–608. https://doi.org/10.1056/NEJMoa2209604

  • Payne, Amanda. n.d. “Summary of Effectiveness of Nirsevimab in Infants.” Accessed October 2, 2024. https://stacks.cdc.gov/view/cdc/157872

  • Pitzer, Virginia E., Cécile Viboud, Wladimir J. Alonso, Tanya Wilcox, C. Jessica Metcalf, Claudia A. Steiner, Amber K. Haynes, and Bryan T. Grenfell. 2015. “Environmental Drivers of the Spatiotemporal Dynamics of Respiratory Syncytial Virus in the United States.” PLoS Pathogens 11 (1): e1004591. https://doi.org/10.1371/journal.ppat.1004591

  • Rha, Brian, Aaron T. Curns, Joana Y. Lively, Angela P. Campbell, Janet A. Englund, Julie A. Boom, Parvin H. Azimi, et al. 2020. “Respiratory Syncytial Virus–Associated Hospitalizations Among Young Children: 2015–2016.” Pediatrics 146 (1): e20193611. https://doi.org/10.1542/peds.2019-3611

  • Surie, Diya, Wesley H. Self, Yuwei Zhu, Katharine A. Yuengling, Cassandra A. Johnson, Carlos G. Grijalva, Fatimah S. Dawood, and Investigating Respiratory Viruses in the Acutely Ill (IVY) Network. 2024. “RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older.” JAMA 332 (13): 1105–7. https://doi.org/10.1001/jama.2024.15775

  • Walsh, Edward E., Gonzalo Pérez Marc, Agnieszka M. Zareba, Ann R. Falsey, Qin Jiang, Michael Patton, Fernando P. Polack, et al. 2023. “Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.” New England Journal of Medicine 388 (16): 1465–77. https://doi.org/10.1056/NEJMoa2213836

  • Wilkins, Deidre, Yuan Yuan, Yue Chang, Anastasia A. Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby-Hamrén, Tianhui Zhang, et al. 2023. “Durability of Neutralizing RSV Antibodies Following Nirsevimab Administration and Elicitation of the Natural Immune Response to RSV Infection in Infants.” Nature Medicine 29 (5): 1172–79. https://doi.org/10.1038/s41591-023-02316-5

  • Zheng, Zhe, Daniel M. Weinberger, and Virginia E. Pitzer. 2022. “Predicted Effectiveness of Vaccines and Extended Half-Life Monoclonal Antibodies against RSV Hospitalizations in Children.” NPJ Vaccines 7 (1): 127. https://doi.org/10.1038/s41541-022-00550-5

Contact us

If you have any questions or any issues, please feel free to contact us:

Clone this wiki locally